JP2007532629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532629A5 JP2007532629A5 JP2007507872A JP2007507872A JP2007532629A5 JP 2007532629 A5 JP2007532629 A5 JP 2007532629A5 JP 2007507872 A JP2007507872 A JP 2007507872A JP 2007507872 A JP2007507872 A JP 2007507872A JP 2007532629 A5 JP2007532629 A5 JP 2007532629A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effector
- composition according
- glyceryl
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 35
- 239000012636 effector Substances 0.000 claims 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims 7
- 239000000194 fatty acid Substances 0.000 claims 7
- 229930195729 fatty acid Natural products 0.000 claims 7
- 102000003982 Parathyroid hormone Human genes 0.000 claims 6
- 108090000445 Parathyroid hormone Proteins 0.000 claims 6
- 239000000199 parathyroid hormone Substances 0.000 claims 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 5
- -1 fatty acid salt Chemical class 0.000 claims 5
- 239000002609 medium Substances 0.000 claims 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical group CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims 4
- 150000007824 aliphatic compounds Chemical class 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- 239000002736 nonionic surfactant Substances 0.000 claims 4
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims 3
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims 3
- 108010051696 Growth Hormone Proteins 0.000 claims 3
- 102000018997 Growth Hormone Human genes 0.000 claims 3
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims 3
- 229960001318 fondaparinux Drugs 0.000 claims 3
- 239000000122 growth hormone Substances 0.000 claims 3
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims 3
- 229960001319 parathyroid hormone Drugs 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical group [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims 3
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000004359 castor oil Substances 0.000 claims 2
- 235000019438 castor oil Nutrition 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims 2
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 claims 2
- 239000001570 sorbitan monopalmitate Substances 0.000 claims 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 1
- QHZLMUACJMDIAE-SFHVURJKSA-N 1-hexadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO QHZLMUACJMDIAE-SFHVURJKSA-N 0.000 claims 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 claims 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical group CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001304 Solutol HS 15 Polymers 0.000 claims 1
- 230000010100 anticoagulation Effects 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 150000001491 aromatic compounds Chemical class 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000003833 bile salt Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 150000001923 cyclic compounds Chemical class 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229940068939 glyceryl monolaurate Drugs 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- LKUNXBRZDFMZOK-UHFFFAOYSA-N rac-1-monodecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(O)CO LKUNXBRZDFMZOK-UHFFFAOYSA-N 0.000 claims 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 claims 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical group CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 claims 1
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 1
- 239000001593 sorbitan monooleate Substances 0.000 claims 1
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 1
- 229940035049 sorbitan monooleate Drugs 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56234504P | 2004-04-15 | 2004-04-15 | |
| PCT/IB2005/004183 WO2006097793A2 (en) | 2004-04-15 | 2005-04-14 | Compositions capable of facilitating penetration across a biological barrier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532629A JP2007532629A (ja) | 2007-11-15 |
| JP2007532629A5 true JP2007532629A5 (https=) | 2009-01-08 |
Family
ID=36822392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007507872A Pending JP2007532629A (ja) | 2004-04-15 | 2005-04-14 | 生物学的障壁を横切る透過を促進し得る組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8241670B2 (https=) |
| EP (1) | EP1742663A2 (https=) |
| JP (1) | JP2007532629A (https=) |
| KR (1) | KR20070044805A (https=) |
| CN (1) | CN101084016A (https=) |
| AU (1) | AU2005329255B2 (https=) |
| CA (1) | CA2563533C (https=) |
| IL (1) | IL178479A (https=) |
| MX (1) | MXPA06011871A (https=) |
| NZ (1) | NZ550320A (https=) |
| WO (1) | WO2006097793A2 (https=) |
Families Citing this family (184)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| ATE405670T1 (de) * | 2002-05-13 | 2008-09-15 | Arexis Ab | Autoimmunerkrankungen und nadph-oxidase-defekte |
| CA2563533C (en) * | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| US20070219131A1 (en) * | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| GB0427267D0 (en) * | 2004-12-13 | 2005-01-12 | Maria Teresa De Magistris | Peptide adjuvants |
| WO2007022345A2 (en) * | 2005-08-17 | 2007-02-22 | Fleming And Company, Pharmaceuticals | Vitamin b12 nasal spray and method of use |
| WO2007029238A2 (en) * | 2005-09-06 | 2007-03-15 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
| AU2006302237C1 (en) * | 2005-10-07 | 2012-11-08 | The University Of Alabama | Multi-functional ionic liquid compositions |
| US20080051451A1 (en) * | 2006-03-15 | 2008-02-28 | Marcel Linschoten | Autoimmune conditions and NADPH oxidase defects |
| EP2004159A1 (en) * | 2006-03-15 | 2008-12-24 | Biovitrum AB (publ) | Autoimmune conditions and nadph oxidase defects |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| EP2037941B8 (en) * | 2006-05-30 | 2015-07-01 | OraHealth Corporation | Cobalamin compositions for treating or preventing mucositis |
| JP2010520852A (ja) * | 2006-10-27 | 2010-06-17 | ジュセッペ・トリジャンテ | 除毛（脱毛）のための化合物と方法 |
| US9918934B2 (en) | 2006-12-12 | 2018-03-20 | Edgar Joel Acosta-Zara | Linker-based lecithin microemulsion delivery vehicles |
| DE102007012644A1 (de) * | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Stabilisierung von Vitamin B12 |
| WO2008132732A2 (en) * | 2007-04-26 | 2008-11-06 | Oramed Pharmaceuticals Inc | Methods and compositions for rectal administration of proteins |
| RU2526904C2 (ru) * | 2007-05-11 | 2014-08-27 | Дзе Борд Оф Риджентс Оф Дзе Юнивёрсити Оф Небраска | Композиции для доставки белков и методы их применения |
| CN101677944A (zh) * | 2007-06-01 | 2010-03-24 | 诺沃-诺迪斯克有限公司 | 稳定的非含水药物组合物 |
| US20110144010A1 (en) * | 2007-06-01 | 2011-06-16 | Novo Nordisk A/S | Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier |
| WO2009017802A1 (en) | 2007-08-01 | 2009-02-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Nitro-fattyacid modulation of type ii diabetes |
| US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
| US8044021B2 (en) * | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
| US8101565B2 (en) * | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| CN106310293A (zh) | 2007-09-27 | 2017-01-11 | 免疫疫苗技术有限公司 | 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用 |
| IL188647A0 (en) | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| NZ588603A (en) * | 2008-03-26 | 2012-03-30 | Oramed Ltd | Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin |
| US8231887B2 (en) * | 2008-04-11 | 2012-07-31 | Basf Corporation | Pesticidal compositions |
| JP2011519373A (ja) | 2008-05-01 | 2011-07-07 | コンプレクザ インコーポレイテッド | ビニル置換脂肪酸 |
| US20110046053A1 (en) | 2008-05-05 | 2011-02-24 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
| RU2517135C2 (ru) * | 2008-05-07 | 2014-05-27 | Меррион Рисерч Iii Лимитед | Композиции пептидов и способы их получения |
| WO2009146523A1 (en) * | 2008-06-05 | 2009-12-10 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| EP2299997A4 (en) | 2008-06-19 | 2012-01-11 | Univ Utah Res Found | USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES |
| US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| JP5740689B2 (ja) | 2008-08-18 | 2015-06-24 | エンテラ バイオ エルティーディー． | タンパク質の経口投与用の方法および組成物 |
| MX2011002688A (es) * | 2008-09-12 | 2011-04-12 | Critical Pharmaceuticals Ltd | Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel. |
| KR101814186B1 (ko) * | 2008-09-17 | 2018-03-14 | 키아스마 인코포레이티드 | 약제학적 조성물 및 연관된 투여방법 |
| WO2010055052A1 (en) * | 2008-11-13 | 2010-05-20 | Novozymes A/S | Detergent composition |
| US8193232B2 (en) * | 2009-02-13 | 2012-06-05 | Topica Pharmaceuticals, Inc. | Anti-fungal formulation |
| CN101862445A (zh) * | 2009-04-16 | 2010-10-20 | 哈药集团生物工程有限公司 | 一种含有蛋白酶抑制剂的口服胰岛素 |
| CN102099011B (zh) | 2009-07-09 | 2016-06-01 | 奥莎迪药品管理有限公司 | 基质载体组合物、方法及用途 |
| EP3045167A1 (en) | 2009-07-31 | 2016-07-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Keto fatty acids as anti-inflammatory agents |
| DK2921486T3 (da) | 2009-08-07 | 2017-11-13 | American Life Science Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme |
| EP2483233A4 (en) | 2009-10-02 | 2013-08-14 | Complexa Inc | HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS |
| US20110311621A1 (en) * | 2010-03-16 | 2011-12-22 | Paul Salama | Pharmaceutical compositions and methods of delvery |
| US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
| US20110319325A1 (en) * | 2010-06-28 | 2011-12-29 | Complexa, Inc. | Multi-component pharmaceuticals for treating diabetes |
| CA2808978A1 (en) | 2010-08-23 | 2012-03-01 | Shmuel Ben-Sasson | Compositions for gastric delivery of active agents |
| CN102466730A (zh) * | 2010-11-19 | 2012-05-23 | 南京神州英诺华医疗科技有限公司 | 一种新的配制血型反定型试剂的方法 |
| US8524662B2 (en) | 2010-12-28 | 2013-09-03 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| US8398611B2 (en) | 2010-12-28 | 2013-03-19 | Depuy Mitek, Inc. | Compositions and methods for treating joints |
| US8455436B2 (en) | 2010-12-28 | 2013-06-04 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| KR20140026354A (ko) | 2011-01-07 | 2014-03-05 | 메리온 리서치 Ⅲ 리미티드 | 경구 투여용 철의 제약 조성물 |
| US20120277155A1 (en) | 2011-02-25 | 2012-11-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
| US9498533B2 (en) | 2011-04-04 | 2016-11-22 | Board Of Regents Of The University Of Nebraska | Drug delivery compositions and methods |
| US8623839B2 (en) | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
| WO2013028501A1 (en) | 2011-08-19 | 2013-02-28 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
| EP2750697A4 (en) | 2011-09-02 | 2015-03-25 | Medtronic Inc | CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
| WO2013038767A1 (ja) * | 2011-09-13 | 2013-03-21 | オリンパス株式会社 | 膵液成分を含有する生体試料中のプロテアーゼの阻害方法 |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| EP3260131A1 (en) | 2012-01-03 | 2017-12-27 | Oramed Ltd. | Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes |
| CN113769074A (zh) | 2012-02-01 | 2021-12-10 | 奥拉姆德有限公司 | 含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法 |
| RU2639483C2 (ru) | 2012-03-19 | 2017-12-21 | Сидара Терапьютикс, Инк. | Режимы дозирования для соединений класса эхинокандинов |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| CN104364260B (zh) | 2012-04-11 | 2017-02-22 | 诺和诺德股份有限公司 | 胰岛素制剂 |
| ES3055223T3 (en) | 2012-05-03 | 2026-02-10 | Alcon Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| JP6360039B2 (ja) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| JP6210982B2 (ja) * | 2012-06-22 | 2017-10-11 | オリンパス株式会社 | 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット |
| AU2013304630A1 (en) * | 2012-08-21 | 2015-02-26 | Glaxo Group Limited | Compositions comprising an antibody and camostat mesylate (cm) |
| CN102940886B (zh) * | 2012-12-13 | 2015-02-18 | 鼎正动物药业（天津）有限公司 | 一种生物屏障渗透剂及其制备方法 |
| WO2014106846A2 (en) | 2013-01-03 | 2014-07-10 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
| EP2956138B1 (en) | 2013-02-15 | 2022-06-22 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| MX368903B (es) | 2013-02-20 | 2019-10-21 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| KR20150141958A (ko) * | 2013-03-12 | 2015-12-21 | 어플라이드 바이오리서치, 인크. | 개선된 약물 전달을 위한 킬레이트화 좌제 |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| JP2016524617A (ja) * | 2013-05-30 | 2016-08-18 | ノヴォ ノルディスク アー／エス | 糖尿病の治療のための新規な経口医薬組成物 |
| CN103301064B (zh) * | 2013-06-04 | 2016-04-20 | 北京四环生物制药有限公司 | 一种白介素-2或其衍生物鼻喷剂及其制备方法 |
| WO2015016682A1 (ko) | 2013-08-01 | 2015-02-05 | 경희대학교 산학협력단 | 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법 |
| EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US9458169B2 (en) | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR101470793B1 (ko) * | 2014-06-30 | 2014-12-08 | 순천향대학교 산학협력단 | 흡수촉진제로서의 펩타이드와 이를 포함하는 조성물 |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| AU2015360485B2 (en) | 2014-12-10 | 2020-06-25 | Amryt Endo, Inc. | Oral octreotide administered in combination with other therapeutic agents |
| US9682099B2 (en) | 2015-01-20 | 2017-06-20 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
| JP7211704B2 (ja) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤 |
| WO2016126830A1 (en) | 2015-02-03 | 2016-08-11 | Chiasma Inc. | Method of treating diseases |
| PT3865484T (pt) | 2015-07-07 | 2024-01-30 | H Lundbeck As | Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas |
| WO2017059451A1 (en) | 2015-10-02 | 2017-04-06 | Complexa, Inc. | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
| WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| EA201891000A1 (ru) | 2015-10-22 | 2018-12-28 | МОДЕРНАТиЭкс, ИНК. | Вакцина против респираторно-синцитиального вируса |
| JP7384512B2 (ja) | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| EP3365009A4 (en) | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | VACCINES AGAINST HERPES SIMPLEX VIRUS |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| PL3394093T3 (pl) | 2015-12-23 | 2022-05-16 | Modernatx, Inc. | Metody stosowania polinukleotydów kodujących ligand ox40 |
| MA43587A (fr) | 2016-01-10 | 2018-11-14 | Modernatx Inc | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 |
| US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| PE20210857A1 (es) | 2016-12-16 | 2021-05-18 | Novo Nordisk As | Composiciones farmaceuticas que contienen insulina |
| JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
| US11485972B2 (en) | 2017-05-18 | 2022-11-01 | Modernatx, Inc. | Modified messenger RNA comprising functional RNA elements |
| EP3638292A1 (en) | 2017-06-14 | 2020-04-22 | ModernaTX, Inc. | Polynucleotides encoding coagulation factor viii |
| WO2019094702A1 (en) | 2017-11-10 | 2019-05-16 | Cocoon Biotech Inc. | Ocular applications of silk-based products |
| EP3714045A1 (en) | 2017-11-22 | 2020-09-30 | Modernatx, Inc. | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia |
| US11939601B2 (en) | 2017-11-22 | 2024-03-26 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| CA3079428A1 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
| WO2019133890A1 (en) * | 2017-12-29 | 2019-07-04 | University Of Kansas | Nanoparticles including a glatiramoid useful in polynucleotide delivery |
| MA51523A (fr) | 2018-01-05 | 2020-11-11 | Modernatx Inc | Polynucléotides codant pour des anticorps anti-virus du chikungunya |
| WO2019157453A1 (en) * | 2018-02-12 | 2019-08-15 | Trilogy Therapeutics, Inc. | Caspofungin compositions for inhalation |
| EP3761962A4 (en) * | 2018-03-07 | 2021-12-15 | ReForm Biologics, Inc. | EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS |
| EP3773745A1 (en) | 2018-04-11 | 2021-02-17 | ModernaTX, Inc. | Messenger rna comprising functional rna elements |
| WO2019226650A1 (en) | 2018-05-23 | 2019-11-28 | Modernatx, Inc. | Delivery of dna |
| CA3100988A1 (en) | 2018-05-25 | 2019-11-28 | Imara Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one |
| US20210145841A1 (en) * | 2018-06-23 | 2021-05-20 | Poviva Corp. | Enhancement of delivery of lipophilic active agents across the blood-brain barrier and methods for treating central nervous system disorders |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| CA3110680A1 (en) | 2018-08-31 | 2020-03-05 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
| WO2020047201A1 (en) | 2018-09-02 | 2020-03-05 | Modernatx, Inc. | Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
| MX2021003015A (es) | 2018-09-13 | 2021-07-15 | Modernatx Inc | Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis. |
| WO2020056155A2 (en) | 2018-09-13 | 2020-03-19 | Modernatx, Inc. | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease |
| JP2022500444A (ja) | 2018-09-14 | 2022-01-04 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ１ファミリー、ポリペプチドａ１をコードするポリヌクレオチド |
| EP3856233A1 (en) | 2018-09-27 | 2021-08-04 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
| WO2020097409A2 (en) | 2018-11-08 | 2020-05-14 | Modernatx, Inc. | Use of mrna encoding ox40l to treat cancer in human patients |
| GB201900728D0 (en) * | 2019-01-18 | 2019-03-06 | Univ Birmingham | Drug delivery system |
| MA55899A (fr) | 2019-05-08 | 2022-03-16 | Modernatx Inc | Polynucléotides codant pour la méthylmalonyl-coa mutase pour le traitement de l'acidémie méthylmalonique |
| JP2022532078A (ja) | 2019-05-08 | 2022-07-13 | アストラゼネカ アクチボラグ | 皮膚及び創傷のための組成物並びにその使用の方法 |
| US20220387628A1 (en) | 2019-06-24 | 2022-12-08 | Modernatx, Inc. | Messenger rna comprising functional rna elements and uses thereof |
| EP3987027A1 (en) | 2019-06-24 | 2022-04-27 | ModernaTX, Inc. | Endonuclease-resistant messenger rna and uses thereof |
| EP4048807A1 (en) | 2019-09-23 | 2022-08-31 | Omega Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein b (apob) gene expression |
| CN114729376A (zh) | 2019-09-23 | 2022-07-08 | 欧米茄治疗公司 | 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法 |
| EP4076527A4 (en) | 2020-01-10 | 2024-05-15 | Consynance Therapeutics, Inc. | Therapeutic combinations of drugs and methods of using them |
| EP4096698A1 (en) | 2020-01-28 | 2022-12-07 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer |
| CA3173528A1 (en) | 2020-03-11 | 2021-09-16 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| EP4158005A1 (en) | 2020-06-01 | 2023-04-05 | ModernaTX, Inc. | Phenylalanine hydroxylase variants and uses thereof |
| CA3181680A1 (en) | 2020-06-12 | 2021-12-16 | University Of Rochester | Encoding and expression of ace-trnas |
| WO2022104131A1 (en) | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| US20240216288A1 (en) | 2021-03-24 | 2024-07-04 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| US20240207374A1 (en) | 2021-03-24 | 2024-06-27 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| US20240226025A1 (en) | 2021-03-24 | 2024-07-11 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| WO2022204370A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
| EP4355882A2 (en) | 2021-06-15 | 2024-04-24 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
| WO2022271776A1 (en) | 2021-06-22 | 2022-12-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| EP4367242A2 (en) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| WO2023004113A2 (en) | 2021-07-22 | 2023-01-26 | The Regents Of The University Of California | Compositions and methods for using purified human rna editing enzymes |
| WO2023056044A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
| AU2023215397A1 (en) | 2022-02-07 | 2024-08-22 | University Of Rochester | Optimized sequences for enhanced trna expression or/and nonsense mutation suppression. |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| WO2023177904A1 (en) | 2022-03-18 | 2023-09-21 | Modernatx, Inc. | Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications |
| US20250221931A1 (en) | 2022-03-25 | 2025-07-10 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
| WO2023196399A1 (en) | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| CN114948913B (zh) * | 2022-05-10 | 2024-10-15 | 苏州大学 | 一种具有生物粘附性的凝胶薄膜及其应用 |
| JP2025519656A (ja) | 2022-06-13 | 2025-06-26 | ビー．エー．アイ． ラボラトリーズ， エルエルシー | インターロイキン－１３結合環状オリゴペプチドおよびその使用方法 |
| CN114933736B (zh) * | 2022-06-17 | 2023-02-10 | 江南大学 | 一种多响应性神经支架材料及其制备方法与应用 |
| CN119907661A (zh) * | 2022-07-05 | 2025-04-29 | G2G生物公司 | 含有司美格鲁肽或其药学上可接受的盐的缓释微球制剂及其制备方法 |
| WO2024026254A1 (en) | 2022-07-26 | 2024-02-01 | Modernatx, Inc. | Engineered polynucleotides for temporal control of expression |
| WO2024044147A1 (en) | 2022-08-23 | 2024-02-29 | Modernatx, Inc. | Methods for purification of ionizable lipids |
| WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| WO2024118866A1 (en) | 2022-12-01 | 2024-06-06 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
| WO2024182301A2 (en) | 2023-02-27 | 2024-09-06 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia |
| WO2024197033A1 (en) | 2023-03-21 | 2024-09-26 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of heart failure |
| EP4704816A1 (en) | 2023-05-03 | 2026-03-11 | ModernaTX, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| EP4716741A2 (en) | 2023-05-23 | 2026-04-01 | Flagship Labs 114, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| WO2025072482A1 (en) | 2023-09-27 | 2025-04-03 | Modernatx, Inc. | Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof |
| WO2025101685A1 (en) | 2023-11-09 | 2025-05-15 | University Of Rochester | Suppression of nonsense mutations using anticodon engineered (ace)-trnas |
| WO2025255199A1 (en) | 2024-06-05 | 2025-12-11 | Modernatx, Inc. | Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof |
| WO2026030209A1 (en) | 2024-07-29 | 2026-02-05 | University Of Rochester | Use of decoding trnas to boost protein expression or function |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE376722B (https=) * | 1971-03-30 | 1975-06-09 | S E Friberg | |
| BE795516A (fr) * | 1972-02-17 | 1973-08-16 | Ciba Geigy | Preparations de peptides huileuses et injectables et procede pour leur preparation |
| US4489097A (en) * | 1976-07-28 | 1984-12-18 | The Procter & Gamble Company | Intravenous solutions with antimicrobial agent |
| JPS53107408A (en) | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
| GB2051574B (en) * | 1979-05-10 | 1984-01-18 | Kyoto Pharma Ind | Adjuvant for promoting absorption of pharmacologically active substances through the rectum |
| US4572915A (en) | 1984-05-01 | 1986-02-25 | Bioglan Laboratories | Clear micellized solutions of fat soluble essential nutrients |
| US4985404A (en) * | 1984-10-04 | 1991-01-15 | Monsanto Company | Prolonged release of biologically active polypeptides |
| US4650665A (en) | 1985-02-08 | 1987-03-17 | Ethicon, Inc. | Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition |
| DE3709861A1 (de) | 1987-03-25 | 1988-10-06 | Henkel Kgaa | Emulgierende suppositoriengrundmassen und daraus hergestellte zaepfchen |
| DE3738236A1 (de) | 1987-11-11 | 1989-05-24 | Euro Celtique Sa | Beisskapsel |
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| NO179479C (no) * | 1988-03-11 | 1996-10-16 | Teikoku Seiyaku Kk | Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat |
| GB8822857D0 (en) * | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
| NZ233403A (en) | 1989-04-28 | 1992-09-25 | Mcneil Ppc Inc | Simulated capsule-like medicament |
| FI920646A0 (fi) | 1989-08-17 | 1992-02-14 | Cortecs Ltd | Farmaceutiska preparat. |
| US5665384A (en) | 1990-04-06 | 1997-09-09 | Rhone-Poulenc Rorer S.A. | Oily capsules of ketoprofen |
| SE9003100D0 (sv) | 1990-09-28 | 1990-09-28 | Kabivitrum Ab | Lipid formulation system |
| IT1243435B (it) | 1990-10-05 | 1994-06-10 | Altergon Sa | Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti |
| US5254331A (en) * | 1991-09-12 | 1993-10-19 | Chanel, Inc. | Skin cream composition |
| EP0661052A1 (en) * | 1991-11-08 | 1995-07-05 | Kyoto Pharmaceutical Industries, Ltd. | Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration |
| US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5246716A (en) | 1992-01-10 | 1993-09-21 | W. Neudorff Gmbh Kg | Fatty acid-based antifungal composition having residual activity |
| IL103224A (en) | 1992-09-18 | 1998-08-16 | Teva Pharma | Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
| US5288492A (en) | 1992-11-13 | 1994-02-22 | Morris Michael A | Decongestant composition containing aloe vera |
| DK17093D0 (da) | 1993-02-15 | 1993-02-15 | Lyfjathroun H F | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
| IT1263840B (it) | 1993-03-30 | 1996-09-04 | Giuseppe Furiosi | Formulazioni orali di ubidecarenone in forma di capsule |
| US5318781A (en) * | 1993-04-06 | 1994-06-07 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
| SE9302135D0 (sv) * | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | New pharmaceutical composition |
| US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| TW402506B (en) * | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| US5462726A (en) | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5561115A (en) * | 1994-08-10 | 1996-10-01 | Bayer Corporation | Low temperature albumin fractionation using sodium caprylate as a partitioning agent |
| GB9417524D0 (en) * | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| KR980700872A (ko) * | 1994-12-28 | 1998-04-30 | 야마구찌 다까시 | 경점막 투여용 제제(transmucosal preparation) |
| US5827534A (en) * | 1995-05-24 | 1998-10-27 | University Of Maryland At Baltimore | Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery |
| US6696413B2 (en) | 1995-06-16 | 2004-02-24 | Hexal Ag | Pharmaceutical preparation with cyclosporin A |
| GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| US5686488A (en) | 1995-08-25 | 1997-11-11 | Alcon Laboratories, Inc. | Polyethoxylated castor oil products as anti-inflammatory agents |
| EP0760237A1 (en) | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
| US5665711A (en) * | 1995-12-12 | 1997-09-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Antitumor composition for oral administration |
| US5858401A (en) * | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6280745B1 (en) * | 1997-12-23 | 2001-08-28 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
| US5726154A (en) * | 1996-06-28 | 1998-03-10 | University Of Utah Research Foundation | Stabilization and oral delivery of calcitonin |
| WO1998002186A1 (en) * | 1996-07-11 | 1998-01-22 | Farmarc Nederland B.V. | Inclusion complex containing indole selective serotonin agonist |
| US6512010B1 (en) * | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| US5760096A (en) * | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
| JPH10265380A (ja) * | 1997-03-17 | 1998-10-06 | Bristol Myers Squibb Co | 抗ガン剤 |
| WO1998042311A1 (en) | 1997-03-25 | 1998-10-01 | Takeda Chemical Industries, Ltd. | Gastrointestinal mucosa-adherent pharmaceutical composition |
| DE69807281T2 (de) | 1997-05-14 | 2003-04-17 | Mitsubishi Chemical Corp., Tokio/Tokyo | Difluprednat enthaltende Zusammensetzungen |
| IT1296914B1 (it) * | 1997-12-01 | 1999-08-03 | Maria Rosa Gasco | Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera |
| IL123143A (en) | 1998-02-02 | 2001-08-26 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
| JPH11246439A (ja) * | 1998-03-02 | 1999-09-14 | Hisamitsu Pharmaceut Co Inc | 経粘膜用吸収促進剤 |
| US6326360B1 (en) * | 1998-03-11 | 2001-12-04 | Grelan Pharmaceuticals Co., Ltd. | Bubbling enteric coated preparations |
| US6322550B2 (en) * | 1998-04-14 | 2001-11-27 | Hisamitsu Pharmaceutical Co., Inc. | Method for transdermal administration of GP IIb/IIIa antagonist |
| IT1302682B1 (it) | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
| GB9823246D0 (en) | 1998-10-24 | 1998-12-16 | Danbiosyst Uk | A nasal drug delivery composition |
| US6838091B2 (en) * | 1998-12-18 | 2005-01-04 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US6368622B2 (en) * | 1999-01-29 | 2002-04-09 | Abbott Laboratories | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption |
| DE60038097T2 (de) | 1999-02-22 | 2009-02-12 | Merrion Research I Ltd. | Feste orale dosierungsform enthaltend einen resorptionsverstärker |
| US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6383527B1 (en) | 1999-03-04 | 2002-05-07 | Nps Pharmaceuticals, Inc. | Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID |
| US6632443B2 (en) * | 2000-02-23 | 2003-10-14 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
| FR2803202B1 (fr) * | 2000-01-03 | 2004-04-16 | Capsulis | Compositions pharmaceutiques destinees a une adminstration par voie orale |
| CN1141974C (zh) * | 2000-06-07 | 2004-03-17 | 张昊 | 结肠定位释放的口服生物制剂 |
| US6664234B1 (en) * | 2000-06-30 | 2003-12-16 | Monsanto Technology Llc | Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin |
| FR2811571B1 (fr) * | 2000-07-11 | 2002-10-11 | Flamel Tech Sa | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif |
| US20020091623A1 (en) * | 2000-12-04 | 2002-07-11 | Daniels Alan F. | System and methods for an electronic real estate trading environment |
| JP5026655B2 (ja) * | 2001-04-18 | 2012-09-12 | プロメティック、バイオサイエンシーズ、インコーポレーテッド | 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体 |
| EP1392272B1 (en) * | 2001-05-11 | 2014-08-06 | Merrion Research III Limited | Permeation enhancers |
| US6528667B2 (en) | 2001-05-14 | 2003-03-04 | Phoenix Research Corporation | Phosphated castor oil and derivatives |
| US20030070584A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| WO2003004001A1 (en) | 2001-07-06 | 2003-01-16 | Lifecycle Pharma A/S | Controlled agglomeration |
| US6720002B2 (en) * | 2001-07-20 | 2004-04-13 | R.P. Scherer Technologies, Inc. | Antihistamine formulations for soft capsule dosage forms |
| CN1335182A (zh) * | 2001-08-08 | 2002-02-13 | 华中科技大学 | 胰岛素口腔喷剂及其制备工艺 |
| KR100425755B1 (ko) * | 2001-08-27 | 2004-04-03 | 주식회사 원진신약 | 이트라코나졸을 함유하는 조성물 및 그 제조방법 |
| US20030095928A1 (en) | 2001-09-19 | 2003-05-22 | Elan Pharma International Limited | Nanoparticulate insulin |
| US20060052404A1 (en) | 2001-10-26 | 2006-03-09 | Rudolph Alfred R | Pharmaceutical formulations comprising substituted xanthine compounds |
| US6710195B2 (en) | 2001-11-26 | 2004-03-23 | Supergen, Inc. | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| AU2002353118A1 (en) | 2001-12-11 | 2003-07-24 | Dor Biopharma, Inc. | Lipid particles and suspensions and uses thereof |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US6890961B2 (en) | 2002-02-01 | 2005-05-10 | Micelle Products, Inc. | Clear micellized formulations of β-carotene and method of treating leukoplakia |
| US20050287203A1 (en) | 2002-05-08 | 2005-12-29 | Nijs De H | Formulation comprising testosteron undecanoate and castor oil |
| CZ294371B6 (cs) | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
| JP4771697B2 (ja) * | 2002-09-24 | 2011-09-14 | サントリーホールディングス株式会社 | 認知能力の正常応答の低下予防、改善又は向上作用を有する組成物 |
| WO2004035624A2 (en) * | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| CA2509365C (en) | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| ATE419846T1 (de) * | 2003-02-07 | 2009-01-15 | Prometic Biosciences Inc | Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese |
| EP1648472A2 (en) | 2003-07-01 | 2006-04-26 | Ranbaxy Laboratories, Ltd. | Stable oral compositions of azithromycin monohydrate |
| WO2005021013A1 (ja) * | 2003-09-01 | 2005-03-10 | Earthus, Inc. | β−ヒドロキシ短〜中鎖脂肪酸重合体 |
| US20070172517A1 (en) * | 2003-09-17 | 2007-07-26 | Ben-Sasson Shmuel A | Compositions capable of facilitation penetration across a biological barrier |
| WO2005034913A1 (ja) | 2003-10-10 | 2005-04-21 | Eisai Co., Ltd. | 新規液剤組成物 |
| AR046773A1 (es) * | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| US20050209441A1 (en) * | 2004-03-22 | 2005-09-22 | Lile Jackson D | Process for promoting proper folding of human serum albumin using a human serum albumin ligand |
| US20070219131A1 (en) | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| US20050256097A1 (en) | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
| US20060014712A1 (en) * | 2004-05-30 | 2006-01-19 | Cemines, Inc. | Controlled delivery of therapeutic compounds |
| US20060002989A1 (en) * | 2004-06-10 | 2006-01-05 | Ahmed Salah U | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
| JP4993852B2 (ja) * | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| AU2005286640A1 (en) * | 2004-09-21 | 2006-03-30 | Anesiva, Inc. | Delivery of polynucleotides |
| JP2008531591A (ja) * | 2005-02-24 | 2008-08-14 | エラン・ファルマ・インターナショナル・リミテッド | ドセタキセルおよびそれらの類似体のナノ粒子製剤 |
| WO2006123360A2 (en) | 2005-03-01 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Microspheres containing octreotide acetate |
| US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
| US20070021325A1 (en) | 2005-07-21 | 2007-01-25 | Mediplex Corporation | Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability |
| US20070104741A1 (en) * | 2005-11-07 | 2007-05-10 | Murty Pharmaceuticals, Inc. | Delivery of tetrahydrocannabinol |
| EP1988886A1 (en) | 2006-02-13 | 2008-11-12 | Intelgenx Corporation | Delayed release pharmaceutical oral dosage form and method of making same |
| US20070224142A1 (en) * | 2006-03-22 | 2007-09-27 | Swaile David F | Hydrogenated castor oil based compositions as a replacement for petrolatum |
| WO2007117556A2 (en) * | 2006-04-06 | 2007-10-18 | Activbiotics, Incorporated | Pharmaceutical compositions and uses thereof |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| US8071136B2 (en) * | 2006-04-21 | 2011-12-06 | Bioactives, Inc. | Water-soluble pharmaceutical compositions of hops resins |
| JP2009539862A (ja) * | 2006-06-09 | 2009-11-19 | メリオン リサーチ Ｉｉｉ リミテッド | 強化剤を含む固体経口投与剤形 |
| RU2453332C2 (ru) * | 2007-10-16 | 2012-06-20 | Байокон Лимитид | Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц |
| RU2517135C2 (ru) * | 2008-05-07 | 2014-05-27 | Меррион Рисерч Iii Лимитед | Композиции пептидов и способы их получения |
| KR101814186B1 (ko) | 2008-09-17 | 2018-03-14 | 키아스마 인코포레이티드 | 약제학적 조성물 및 연관된 투여방법 |
-
2005
- 2005-04-14 CA CA2563533A patent/CA2563533C/en not_active Expired - Lifetime
- 2005-04-14 US US11/547,568 patent/US8241670B2/en active Active
- 2005-04-14 CN CNA2005800147113A patent/CN101084016A/zh active Pending
- 2005-04-14 WO PCT/IB2005/004183 patent/WO2006097793A2/en not_active Ceased
- 2005-04-14 NZ NZ550320A patent/NZ550320A/en not_active IP Right Cessation
- 2005-04-14 EP EP05857653A patent/EP1742663A2/en not_active Withdrawn
- 2005-04-14 US US11/105,763 patent/US20050232981A1/en not_active Abandoned
- 2005-04-14 KR KR1020067023930A patent/KR20070044805A/ko not_active Withdrawn
- 2005-04-14 AU AU2005329255A patent/AU2005329255B2/en not_active Expired
- 2005-04-14 JP JP2007507872A patent/JP2007532629A/ja active Pending
- 2005-04-14 MX MXPA06011871A patent/MXPA06011871A/es unknown
-
2006
- 2006-10-05 IL IL178479A patent/IL178479A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532629A5 (https=) | ||
| JP7252934B2 (ja) | 医薬組成物および関連する送達方法 | |
| Perry et al. | Recent advances in encapsulation, protection, and oral delivery of bioactive proteins and peptides using colloidal systems | |
| Pakulska et al. | Encapsulation-free controlled release: Electrostatic adsorption eliminates the need for protein encapsulation in PLGA nanoparticles | |
| ES2286157T3 (es) | Procedimiento de transicion de fase inducida para la produccion de microparticulas que continen agentes activos hidrofogos. | |
| US20220023424A1 (en) | Peroxide removal from drug delivery vehicle | |
| ES2149613T5 (es) | Procedimiento para la preparacion de microcapsulas de materias activas recubiertas por un polimero y nuevas microcapsulas obtenidas en particular segun dicho procedimiento. | |
| US5840338A (en) | Loading of biologically active solutes into polymer gels | |
| Torres et al. | Amphiphilic polyanhydrides for protein stabilization and release | |
| Speranza et al. | Influence of emulsifier structure on lipid bioaccessibility in oil–water nanoemulsions | |
| US7141542B2 (en) | Method for stabilizing biomolecules in liquid formulations | |
| Liu et al. | Immobilization and bioactivity of glucose oxidase in hydrogel microspheres formulated by an emulsification–internal gelation–adsorption–polyelectrolyte coating method | |
| US20030059402A1 (en) | Aquespheres, their preparation and uses thereof | |
| MXPA05009493A (es) | Composicion de insulina oral y metodos para producirla y utilizarla. | |
| US8932633B2 (en) | Polysaccharide microparticles containing biological agents: their preparation and applications | |
| RU2013113201A (ru) | Иммуногенная композиция | |
| KR20080034838A (ko) | 골 형태형성 단백질 제형 | |
| Velasco-Salgado et al. | The role of polymeric biomaterials in the treatment of articular osteoarthritis | |
| JP2008530204A (ja) | タンパク質薬物の徐放性組成物 | |
| Grinberg et al. | Highly porous bioresorbable scaffolds with controlled release of bioactive agents for tissue-regeneration applications | |
| Yuan et al. | Preparation of protein-loaded sustained-release microspheres via ‘solid-in-oil-in-hydrophilic oil-in-ethanol (S/O/hO/E)’emulsification | |
| Valachová et al. | Progress in hyaluronan-based nanoencapsulation systems for smart drug release and medical applications | |
| AU2017300392B2 (en) | Methods and compositions for maintaining the conformation and structural integrity of biomolecules | |
| KR20070042598A (ko) | 단백질 약물 함유 지속방출형 고분자 미립구의 제조방법 | |
| KR100908517B1 (ko) | 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법 |